It would be interesting to test whether increasing the SNARE protein pool and treatment with inaxaplin complement each other in treating APOL1 nephropathy, as both act by binding APOL1 protein and, we suspect, act through different pathways. This evidence concerns the gene APOL1 and kidney disorder.